Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axonics Inc (NQ: AXNX )

51.78 +1.84 (+3.69%)
Streaming Delayed Price Updated: 12:25 PM EDT, May 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 112,117
Open 49.95
Bid (Size) 51.58 (2)
Ask (Size) 51.81 (1)
Prev. Close 49.94
Today's Range 49.26 - 51.84
52wk Range 38.41 - 79.81
Shares Outstanding 46,134,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Analyst Ratings for Axonics
Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings: 
Via Benzinga
Axonics® Reports First Quarter 2022 Financial Results
From Axonics, Inc.
Via Business Wire

Performance

YTD
-11.80%
-11.80%
1 Month
-12.29%
-12.29%
3 Month
+7.75%
+7.75%
6 Month
-15.36%
-15.36%
1 Year
-5.64%
-5.64%

More News

Read More
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Axonics® to Participate in BofA Securities 2022 Healthcare Conference
From Axonics, Inc.
Via Business Wire
Axonics: Q4 Earnings Insights
Via Benzinga
What 4 Analyst Ratings Have To Say About Axonics
Via Benzinga
Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System
From Axonics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Axonics® to Report First Quarter 2022 Financial Results on May 5
From Axonics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Via Benzinga
Axonics® Launches Direct to Consumer Television Advertising Campaign
From Axonics, Inc.
Via Business Wire
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
Via Benzinga
FDA Approves Axonics' Recharge-Free Sacral Neuromodulation System
Via Benzinga
A Peek Into The Markets: US Stock Futures Gain Following Monday's Sell-Off
Via Benzinga
5 Stocks To Watch - Tuesday, Mar. 8
Via Talk Markets
5 Stocks To Watch For March 8, 2022
Via Benzinga
Analyst Ratings For Axonics
Via Benzinga
Axonics® Reports Fourth Quarter and Fiscal Year 2021 Financial Results
From Axonics, Inc.
Via Business Wire
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Via Benzinga
Axonics® to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24
From Axonics, Inc.
Via Business Wire
Axonics® to Participate in SVB Leerink Virtual Healthcare Conference
From Axonics, Inc.
Via Business Wire
New Study Finds More Than 60% of Adult Women in the U.S. Experience Urinary Incontinence
From Axonics, Inc.
Via Business Wire
Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue
From Axonics, Inc.
Via Business Wire
Axonics® CEO Raymond W. Cohen Receives Lifetime Entrepreneurial Achievement Award by the Southern California Biomedical Council
From Axonics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.